Kezar Life Sciences (KZR) Q4 2024 Earnings Call March 25, 2025 08:00 AM ET Company Participants Christopher Kirk - CEO & Co-FounderCraig Lammert - Associate Professor of MedicineGideon Hirschfield - ProfessorMatt Phipps - Group Head - Biotechnology Conference Call Participants Divya Rao - AnalystMaury Raycroft - Equity Research AnalystDerek Archila - AnalystMitchell Kapoor - Director, Senior Biotechnology Analyst Operator Good day, everyone. My name is Shell, and I will be your conference operator today. At ...

Kezar Life Sciences, Inc. (KZR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing ...

& KEZAR Selective Targets. Broad Impact. Uniquely Powerful Approaches to Tackling the Toughest Diseases Corporate Overview September 2021 www.kezarlifesciences.com Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circums ...

Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Corporate Presentation September 2020 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statem ...

Kezar Life Sciences, Inc. (NASDAQ:KZR) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Celia Economides - Senior Vice President of Strategy & External Affairs John Fowler - Chief Executive Officer Noreen Henig - Chief Medical Officer Christopher Kirk - President & Chief Scientific Officer Marc Belsky - Chief Financial Officer Conference Call Participants Blair Cohen - H.C. Wainwright Kenneth Atkins - Cowen & Company Matt Phipps - William Blair Operator Greetings and welcome t ...

Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Corporate Presentation August 2020 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statement ...

Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Corporate Presentation March 2020 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements ...

Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Investor Presentation October 2019 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statement ...

Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Investor Presentation September 2019 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking stateme ...

Revolutionizing the Treatment of Autoimmune Disorders and Malignancies Phase 1b MISSION Study Data EULAR 2019 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "plan," "anticipate," "target," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking state ...